HK Stock MarketDetailed Quotes

01681 CONSUN PHARMA

Watchlist
  • 7.800
  • -0.130-1.64%
Not Open Dec 13 16:08 CST
6.62BMarket Cap7.23P/E (TTM)

CONSUN PHARMA Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q6)Jun 30, 2024
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
(FY)Dec 31, 2020
(Q6)Jun 30, 2020
(FY)Dec 31, 2019
Turnover
13.30%1.27B
10.71%2.59B
12.70%1.12B
14.43%2.34B
12.07%993.53M
16.65%2.04B
15.76%886.53M
1.42%1.75B
-18.62%765.86M
-6.28%1.73B
Operating income
13.30%1.27B
10.71%2.59B
12.70%1.12B
14.43%2.34B
12.07%993.53M
16.65%2.04B
15.76%886.53M
1.42%1.75B
-18.62%765.86M
-6.28%1.73B
Cost of sales
-13.33%-321.03M
-15.90%-668.44M
-10.89%-283.26M
-11.48%-576.74M
-13.38%-255.44M
-19.98%-517.32M
-15.97%-225.29M
7.65%-431.16M
23.49%-194.27M
-1.59%-466.85M
Operating expenses
-13.33%-321.03M
-15.90%-668.44M
-10.89%-283.26M
-11.48%-576.74M
-13.38%-255.44M
-19.98%-517.32M
-15.97%-225.29M
7.65%-431.16M
23.49%-194.27M
-1.59%-466.85M
Gross profit
13.28%947.52M
9.01%1.92B
13.32%836.42M
15.42%1.76B
11.62%738.09M
15.56%1.53B
15.68%661.24M
4.78%1.32B
-16.82%571.59M
-8.89%1.26B
Selling expenses
-13.78%-411.91M
-10.40%-852.21M
-10.57%-362.03M
-24.50%-771.96M
-18.28%-327.42M
-14.20%-620.04M
-23.55%-276.81M
-0.69%-542.93M
18.32%-224.04M
3.98%-539.2M
Administrative expenses
1.49%-134.71M
2.14%-315.6M
-1.07%-136.74M
-15.20%-322.5M
-31.87%-135.3M
-37.86%-279.96M
-16.87%-102.6M
-25.75%-203.07M
-8.66%-87.79M
8.52%-161.49M
Impairment and provision
-47.69%9.17M
-61.23%12.6M
37.08%17.53M
80.09%32.49M
850.22%12.79M
161.45%18.04M
109.28%1.35M
92.59%-29.36M
-48.67%-14.51M
---396.48M
-Goodwill impairment
----
----
----
----
----
----
----
----
----
---326.14M
-Other impairment is provision
-47.69%9.17M
-61.23%12.6M
37.08%17.53M
80.09%32.49M
850.22%12.79M
161.45%18.04M
109.28%1.35M
58.26%-29.36M
-48.67%-14.51M
---70.35M
Special items of operating profit
25.74%37.26M
110.16%118.5M
16.44%29.63M
-11.04%56.39M
-14.47%25.45M
7.75%63.38M
144.70%29.76M
3,954.91%58.83M
1,489.83%12.16M
30.45%-1.53M
Operating profit
16.25%447.33M
16.85%884.97M
22.70%384.81M
6.85%757.33M
0.22%313.61M
17.12%708.77M
21.57%312.93M
271.92%605.14M
-19.92%257.41M
-74.74%162.71M
Financing cost
-85.58%-13.38M
-94.49%-21.26M
-76.04%-7.21M
15.28%-10.93M
21.89%-4.09M
39.70%-12.91M
54.40%-5.24M
26.31%-21.4M
0.23%-11.49M
-5.73%-29.04M
Earning before tax
14.92%433.96M
15.72%863.7M
22.00%377.61M
7.26%746.39M
0.59%309.52M
19.21%695.86M
25.12%307.69M
336.72%583.74M
-20.65%245.92M
-78.33%133.66M
Tax
-10.82%-33M
-23.05%-77.15M
-114.56%-29.78M
42.35%-62.7M
77.90%-13.88M
-6.62%-108.74M
-28.91%-62.79M
-44.59%-101.99M
2.55%-48.7M
40.83%-70.54M
After-tax profit from continuing operations
15.27%400.96M
15.04%786.55M
17.65%347.83M
16.45%683.7M
20.72%295.64M
21.87%587.12M
24.18%244.91M
663.19%481.74M
-24.13%197.21M
-87.31%63.12M
Earning after tax
15.27%400.96M
15.04%786.55M
17.65%347.83M
16.45%683.7M
20.72%295.64M
21.87%587.12M
24.18%244.91M
663.19%481.74M
-24.13%197.21M
-87.31%63.12M
Minority profit
1,967.19%1.2M
155.70%2.02M
94.12%-64K
125.86%790K
81.02%-1.09M
82.08%-3.06M
50.84%-5.74M
-2.08%-17.05M
-211.44%-11.67M
-151.96%-16.7M
Profit attributable to shareholders
14.91%399.77M
14.88%784.53M
17.24%347.89M
15.71%682.91M
18.39%296.73M
18.32%590.17M
19.99%250.64M
524.89%498.79M
-16.27%208.89M
-82.85%79.82M
Basic earnings per share
13.14%0.4987
15.12%0.99
17.77%0.4408
16.22%0.86
19.51%0.3743
21.31%0.74
23.94%0.3132
577.78%0.61
-13.72%0.2527
-83.47%0.09
Diluted earnings per share
12.89%0.493
13.95%0.98
16.98%0.4367
17.81%0.86
19.76%0.3733
19.67%0.73
23.35%0.3117
577.78%0.61
-12.01%0.2527
-83.02%0.09
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Audit Opinions
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
Auditor
--
KPMG
--
KPMG
--
KPMG
--
KPMG
--
KPMG
(Q6)Jun 30, 2024(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021(FY)Dec 31, 2020(Q6)Jun 30, 2020(FY)Dec 31, 2019
Turnover 13.30%1.27B10.71%2.59B12.70%1.12B14.43%2.34B12.07%993.53M16.65%2.04B15.76%886.53M1.42%1.75B-18.62%765.86M-6.28%1.73B
Operating income 13.30%1.27B10.71%2.59B12.70%1.12B14.43%2.34B12.07%993.53M16.65%2.04B15.76%886.53M1.42%1.75B-18.62%765.86M-6.28%1.73B
Cost of sales -13.33%-321.03M-15.90%-668.44M-10.89%-283.26M-11.48%-576.74M-13.38%-255.44M-19.98%-517.32M-15.97%-225.29M7.65%-431.16M23.49%-194.27M-1.59%-466.85M
Operating expenses -13.33%-321.03M-15.90%-668.44M-10.89%-283.26M-11.48%-576.74M-13.38%-255.44M-19.98%-517.32M-15.97%-225.29M7.65%-431.16M23.49%-194.27M-1.59%-466.85M
Gross profit 13.28%947.52M9.01%1.92B13.32%836.42M15.42%1.76B11.62%738.09M15.56%1.53B15.68%661.24M4.78%1.32B-16.82%571.59M-8.89%1.26B
Selling expenses -13.78%-411.91M-10.40%-852.21M-10.57%-362.03M-24.50%-771.96M-18.28%-327.42M-14.20%-620.04M-23.55%-276.81M-0.69%-542.93M18.32%-224.04M3.98%-539.2M
Administrative expenses 1.49%-134.71M2.14%-315.6M-1.07%-136.74M-15.20%-322.5M-31.87%-135.3M-37.86%-279.96M-16.87%-102.6M-25.75%-203.07M-8.66%-87.79M8.52%-161.49M
Impairment and provision -47.69%9.17M-61.23%12.6M37.08%17.53M80.09%32.49M850.22%12.79M161.45%18.04M109.28%1.35M92.59%-29.36M-48.67%-14.51M---396.48M
-Goodwill impairment ---------------------------------------326.14M
-Other impairment is provision -47.69%9.17M-61.23%12.6M37.08%17.53M80.09%32.49M850.22%12.79M161.45%18.04M109.28%1.35M58.26%-29.36M-48.67%-14.51M---70.35M
Special items of operating profit 25.74%37.26M110.16%118.5M16.44%29.63M-11.04%56.39M-14.47%25.45M7.75%63.38M144.70%29.76M3,954.91%58.83M1,489.83%12.16M30.45%-1.53M
Operating profit 16.25%447.33M16.85%884.97M22.70%384.81M6.85%757.33M0.22%313.61M17.12%708.77M21.57%312.93M271.92%605.14M-19.92%257.41M-74.74%162.71M
Financing cost -85.58%-13.38M-94.49%-21.26M-76.04%-7.21M15.28%-10.93M21.89%-4.09M39.70%-12.91M54.40%-5.24M26.31%-21.4M0.23%-11.49M-5.73%-29.04M
Earning before tax 14.92%433.96M15.72%863.7M22.00%377.61M7.26%746.39M0.59%309.52M19.21%695.86M25.12%307.69M336.72%583.74M-20.65%245.92M-78.33%133.66M
Tax -10.82%-33M-23.05%-77.15M-114.56%-29.78M42.35%-62.7M77.90%-13.88M-6.62%-108.74M-28.91%-62.79M-44.59%-101.99M2.55%-48.7M40.83%-70.54M
After-tax profit from continuing operations 15.27%400.96M15.04%786.55M17.65%347.83M16.45%683.7M20.72%295.64M21.87%587.12M24.18%244.91M663.19%481.74M-24.13%197.21M-87.31%63.12M
Earning after tax 15.27%400.96M15.04%786.55M17.65%347.83M16.45%683.7M20.72%295.64M21.87%587.12M24.18%244.91M663.19%481.74M-24.13%197.21M-87.31%63.12M
Minority profit 1,967.19%1.2M155.70%2.02M94.12%-64K125.86%790K81.02%-1.09M82.08%-3.06M50.84%-5.74M-2.08%-17.05M-211.44%-11.67M-151.96%-16.7M
Profit attributable to shareholders 14.91%399.77M14.88%784.53M17.24%347.89M15.71%682.91M18.39%296.73M18.32%590.17M19.99%250.64M524.89%498.79M-16.27%208.89M-82.85%79.82M
Basic earnings per share 13.14%0.498715.12%0.9917.77%0.440816.22%0.8619.51%0.374321.31%0.7423.94%0.3132577.78%0.61-13.72%0.2527-83.47%0.09
Diluted earnings per share 12.89%0.49313.95%0.9816.98%0.436717.81%0.8619.76%0.373319.67%0.7323.35%0.3117577.78%0.61-12.01%0.2527-83.02%0.09
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Audit Opinions --Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion
Auditor --KPMG--KPMG--KPMG--KPMG--KPMG

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Traditional Chinese Medicine
Traditional Chinese Medicine
Intraday-1.45%